BidaskClub lowered shares of Catalent, Inc. (NYSE:CTLT) from a buy rating to a hold rating in a research note published on Tuesday morning.

Several other equities analysts also recently commented on CTLT. Bank of America Corporation reiterated a buy rating and set a $38.00 price target (up previously from $37.00) on shares of Catalent in a report on Friday, July 21st. Zacks Investment Research downgraded Catalent from a buy rating to a hold rating in a report on Friday, August 18th. Piper Jaffray Companies reiterated a buy rating and set a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. J P Morgan Chase & Co reiterated a buy rating and set a $40.00 price target on shares of Catalent in a report on Tuesday, August 29th. Finally, Jefferies Group LLC reiterated a hold rating and set a $38.00 price target (up previously from $35.00) on shares of Catalent in a report on Tuesday, August 29th. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $42.11.

Catalent (NYSE:CTLT) opened at $38.20 on Tuesday. The firm has a market cap of $5,120.00, a P/E ratio of 26.06, a P/E/G ratio of 2.40 and a beta of 1.49. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. Catalent has a 52-week low of $22.94 and a 52-week high of $43.39.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.16 earnings per share. equities analysts expect that Catalent will post 1.46 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Catalent, Inc. (CTLT) Downgraded by BidaskClub” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/18/catalent-inc-ctlt-downgraded-by-bidaskclub.html.

In other Catalent news, SVP Christine Dolan sold 1,594 shares of Catalent stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.70% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in CTLT. State of Wisconsin Investment Board acquired a new stake in Catalent in the second quarter worth about $3,334,000. Chicago Equity Partners LLC grew its position in shares of Catalent by 20.4% during the 2nd quarter. Chicago Equity Partners LLC now owns 109,825 shares of the company’s stock worth $3,855,000 after buying an additional 18,600 shares during the period. Airain ltd acquired a new position in shares of Catalent during the 2nd quarter worth about $3,524,000. Renaissance Technologies LLC acquired a new position in shares of Catalent during the 2nd quarter worth about $23,092,000. Finally, Sei Investments Co. grew its position in shares of Catalent by 79,537.0% during the 2nd quarter. Sei Investments Co. now owns 43,004 shares of the company’s stock worth $1,509,000 after buying an additional 42,950 shares during the period. 95.65% of the stock is owned by institutional investors and hedge funds.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Stock Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related stocks with our FREE daily email newsletter.